This article is more than 5 years old. Information may no longer be current.

EyeGate records no revenue in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported it did not recognize any revenue for the second quarter of 2019, according to a press release.

In 2018 and the first quarter of 2019, all revenue was attributed to milestone payments from Bausch Health.

Research and development expenses decreased from $1.838 million a year ago to $0.764 million as a result of decreases in activity related to EGP-437 (dexamethasone phosphate), personnel costs, and manufacturing work and market research costs related to the Ocular Bandage Gel (hyaluronic acid).

General and administrative expenses were $1.106 million in the second quarter compared with $1.203 million during the same time in 2018.

The company had cash and cash equivalents of $4.465 million as of June 30.